Erudio Bio — 6-Minute IR Pitch Rehearsal Guide @ RESI San Diego
Jeonbuk Advanced Bio Boost-Up Showcase @ RESI San Diego (22-Jun-2026)
Slot: 10:44–10:56 (Pitch #3 of 7) · 6 min talk + 6 min Q&A · English
0. The one reframe before you rehearse
A 6-minute showcase pitch does not close a round. Its only jobs:
- Be the company they remember.
- Make them want the 1:1.
So: ONE spine, ONE killer hook, the BEST proof point, a clear ask. Do not tour all 13 slides. Recommended spine: “AI medicine has a credibility gap. We close it with measurement-calibrated physics — the same discipline that made semiconductors trustworthy.”
If the audience remembers ONE sentence, make it that.
1. Slide cut-list (use ~8 slides, not 13)
| Beat | Use slide | Cut / skip |
|---|---|---|
| Hook | S1 Title | — |
| What we are | S3 Tech Stack (or S6) | — |
| Proof #1 (WOW) | S8 bioTCAD 100% vs 12.5% | — |
| Proof #2 (moat) | S4 VSA (+ glance S7) | — |
| Markets + model | S11 Diagnostic (or new Markets slide) | — |
| Traction + Ask | NEW slide — make this | — |
| Team / Board | S13 (one line, don’t read) | — |
| Skip entirely | S2, S5, S9, S10, S12 (fold S12 founder-TCAD line into the hook; mention biodefense S10 in one phrase) |
Build tonight: one “Traction & Ask” slide (Gates $1M · 21 patents · SNUH/Keimyung · MFDS track · then: raising $X for milestones Y).
2. The 6-minute script (≈700 words — say it at a measured pace)
Fill the [brackets] with your real numbers. Practice out loud, time it, aim for 5:30 to leave breathing room.
[0:00–0:30 · HOOK · S1] “AI is rewriting medicine — but it has a trust problem. Today’s AI can tell you a molecule might bind. It can’t tell you why, and it breaks down in new chemical space it has never seen. In medicine, ‘probably’ isn’t good enough. My co-founders and I have solved this exact problem before — not in biology, in semiconductors. For two decades we built the simulation software the entire chip industry runs on. We’re now bringing that discipline to medicine. We are Erudio Bio.”
[0:30–1:15 · THE INSIGHT · S3] “Here’s the lesson from chips. Semiconductor design became trustworthy because of one principle: you validate your simulation against your own physical measurements. Calibrate to reality, and the model becomes reliably right. Biology never had that loop — because it never had the measurement engine. Erudio builds both halves. One: VSA, a chip that generates massive, high-quality biological measurement data. Two: bioTCAD, a physics-based simulator calibrated to that data. One core competency — measurement-calibrated physics — two products.”
[1:15–2:15 · PROOF #1 — bioTCAD · S8] “Let me show you what that buys. We tested binding prediction on antiviral peptides. We took one starting molecule, measured it, and calibrated bioTCAD to that single measurement. Then we predicted binding for eight related designs — blind. State-of-the-art in-silico AI got 12.5% correct — one out of eight. bioTCAD got 100% — eight out of eight — including correctly calling the ones that don’t bind, which is exactly where every other method fails. That is the difference between pattern-matching and physics you can trust.”
[2:15–3:00 · PROOF #2 — VSA moat · S4] “And bioTCAD is only this good because of the data underneath it. VSA is a Stanford spin-out — ten years of development, 21 issued patents. It’s a chip-based force-spectroscopy array that doesn’t just detect molecules; it measures the force of their interactions. We validated it in human serum on a six-marker cytokine panel — removing the cross-reactivity errors that break conventional multiplexing. Nobody else has this measurement engine. That is our moat.”
[3:00–3:50 · MARKETS + MODEL · S11] “One platform, three markets. We lead commercially with clinical diagnostics — with hospital partners including Seoul National University Hospital — because it earns revenue today and feeds the data engine. bioTCAD is our high-margin expansion into pharma drug discovery, where calibrated simulation will become required for every launch — the way chip design can’t happen without EDA software. And biodefense — field detection of threats — we pursue with non-dilutive government funding. Diagnostics pays the bills. bioTCAD is the prize.”
[3:50–4:35 · TRACTION · NEW slide] “We’re not just a thesis. We have a one-million-dollar Gates Foundation grant validating the science non-dilutively. 21 issued patents. Clinical partnerships with major hospitals. An active regulatory track for VSA. And early government interest on biodefense. The hard part is built — the platform works, and it’s validated.”
[4:35–5:10 · TEAM / BOARD · S13] “And we’re backed by people who’ve done this at scale. Michael Cola, who led Shire to its $62-billion sale to Takeda. Stanford genomics pioneers Ron Davis, Michael Snyder, and Will Greenleaf. And national-security leaders from the CIA and the White House guiding our biodefense work. Industry, academia, and government — in one room.”
[5:10–6:00 · ASK + CLOSE · NEW slide] “We’re raising [$___ bridge round] to [hit milestones: e.g., scale diagnostic deployments and close our first pharma bioTCAD engagements]. If you take one thing from today: AI medicine has a credibility gap — and Erudio is the measurement layer that closes it, the same way we made silicon trustworthy. I’d love to continue this conversation. Thank you.”
3. Delivery notes
- First 20 seconds decide everything. Judges form an impression fast. Lead with the hook, not “Hello, my name is…”.
- One idea per slide. Never read the slide. The slide is the visual; you are the story.
- Slow down. International panel, English pitch — clarity beats speed. Pauses are powerful.
- Engineer the bioTCAD moment (S8). Pause before “100%.” Let it land. That’s your Han Dai moment.
- Land the ask. Say the number out loud. Vague ask = no follow-up.
- End on the memorable line, then stop. Don’t trail off.
4. Q&A bank (your other 6 minutes — this is where relationships form)
Q&A is half your time and where the actual investor interest forms. Answer crisply, never defensive, and turn each into a 1:1 hook: “happy to go deep on that in a 1:1.”
Q1. “You have two products and three markets — what are you, and where does the money go?” (the focus question — they WILL ask) → “We’re a measurement-calibrated physics platform. The capital goes to the diagnostics wedge for near-term revenue and data, which compounds into bioTCAD. One focus: build the data-to-simulation loop and monetize it first in diagnostics.”
Q2. “How is bioTCAD different from AlphaFold / Boltz / FEP / Schrödinger?” (Han Dai will ask this) → “Those are powerful at pattern recognition and static structure. They don’t reliably predict binding in novel space because they aren’t calibrated to physical force measurements. bioTCAD fits force-field parameters to our own VSA measurements — that’s why it called 8/8 where state-of-the-art called 1/8. It’s the TCAD principle: calibrate to measurement.”
Q3. “Eight peptides is a small dataset. Does it generalize?” (be honest) → “Agreed — that’s a deliberately hard blind test, not the whole story. The point is the method: calibration to measurement generalizes because physics generalizes. Scaling the validation across targets is exactly what this round funds.”
Q4. “Regulatory and reimbursement path for VSA diagnostics?” (Galzahr / Gotbetter) → “Active MFDS track in Korea; US path is novel-modality, so likely De Novo / 510(k). Commercially we lead with hospital networks already partnered. Happy to walk the regulatory map in a 1:1.”
Q5. “IP and freedom to operate?” (Andrew Strong, IP lawyer) → “21 issued patents from 10 years of Stanford development. Our claims anchor to the physical force-spectroscopy measurement — which keeps them on solid §101 footing — while claiming broadly at the level of molecular-interaction physics. Drug discovery is one embodiment.”
Q6. “What am I investing in — the US or the Korea entity?” (confirm your real structure first) → “Erudio Bio, Inc. is the US IP and investment vehicle; the Korea entity is the commercial/clinical arm for the Asian market and non-dilutive Korean funding. You’d be investing in the US Inc.” (adjust to your actual cap structure.)
Q7. “Who is full-time? The board is advisory.” → Name your full-time founders/operators and what each owns (chip/biophysics, AI/software, biology). Show execution muscle, not just advisors.
Q8. “Chip manufacturing / scalability?” (Amici / strategic) → “Array-based architecture designed to scale — dozens to thousands of assays by adding modules. Our founders’ semiconductor-manufacturing background is a direct advantage here.” (Strategic-partner hook for FUJIFILM.)
Q9. “Revenue to date beyond grants?” → Be honest about stage; pivot to the de-risking (Gates, partners, validation) and what the round unlocks commercially.
Q10. “What are you raising, valuation, milestones?” → Have a crisp one-liner ready: “$X on $Y, which funds [milestones] over [N months] to reach [Series A inflection].” Never improvise this.
5. Tonight’s checklist
- Build the Traction & Ask slide (fill real round size + milestones)
- Pull deck down to the ~8-slide cut-list
- Rehearse the script out loud, timed — twice. Cut to fit 5:30.
- Memorize the hook and the closing line cold
- Prep Q&A answers #1, #2, #10 until automatic
- Arrive JULEP Venue by 9:30 (separate from main convention center)